David Hong

David Hong

Company: University of Texas M.D. Anderson Cancer Center

Job title: Professor, Deputy Chair of the Department of Investigational Cancer Therapeutics


The Clinician Hour – Patient Perspectives & Clinical Insights 1:00 pm

As the number of RAS targeted therapies within the clinic reaches record high, it is essential that we reflect, learn and act on the results we receive. With this, this session will bring together clinicians from across the globe working first-hand with patients and clinical candidates, as they share experiences, thoughts, and reflections to ultimately…Read more

day: Track B - Day 2 PM

PANEL DISCUSSION: On the Horizon – Discussing the Post-Approval Landscape for Successful RAS Drugs Beyond AMG510 3:45 pm

As this industry progresses from the first-in-class approval for an anti-RAS therapy, the landscape of RAS targeting is more exciting than ever and there is a clear roadmap toward future clinical success. This panel discussion will consider what is next for the RAS community, what will be the next emerging strategy to reach the patient…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.